Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ruth Ann Luna is active.

Publication


Featured researches published by Ruth Ann Luna.


Alimentary Pharmacology & Therapeutics | 2015

Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome.

Bruno P. Chumpitazi; Julia L. Cope; Emily B. Hollister; Cynthia M. Tsai; Ann R. McMeans; Ruth Ann Luna; James Versalovic; Robert J. Shulman

A low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet can ameliorate symptoms in adult irritable bowel syndrome (IBS) within 48 h.


Current Opinion in Biotechnology | 2015

Gut brain axis: diet microbiota interactions and implications for modulation of anxiety and depression.

Ruth Ann Luna; Jane A. Foster

The human gut microbiome is composed of an enormous number of microorganisms, generally regarded as commensal bacteria. Without this inherent microbial community, we would be unable to digest plant polysaccharides and would have trouble extracting lipids from our diet. Resident gut bacteria are an important contributor to healthy metabolism and there is significant evidence linking gut microbiota and metabolic disorders such as obesity and diabetes. In the past few years, neuroscience research has demonstrated the importance of microbiota in the development of brain systems that are vital to both stress reactivity and stress-related behaviours. Here we review recent literature that examines the impact of diet-induced changes in the microbiota on stress-related behaviours including anxiety and depression.


Journal of Clinical Microbiology | 2007

DNA Pyrosequencing-Based Bacterial Pathogen Identification in a Pediatric Hospital Setting

Ruth Ann Luna; Lea R. Fasciano; Shaunte C. Jones; Bobby L. Boyanton; Trang T. Ton; James Versalovic

ABSTRACT Sole reliance on biochemical methods can limit the clinical microbiology laboratorys ability to identify bacterial pathogens. This study describes the incorporation of DNA pyrosequencing-based identification for routine pathogen identification of atypical clinical isolates in a large childrens hospital. The assay capitalized on the highly conserved nature of 16S rRNA genes by positioning amplification and sequencing primers in conserved target sequences flanking the variable V1 and V3 regions. A total of 414 isolates of 312 pediatric patients were tested by DNA pyrosequencing during the time period from December 2003 to July 2006. Seventy-eight different genera were specified by DNA pyrosequencing, and isolates were derived from diverse specimen types. By integrating DNA sequencing of bacterial pathogens with conventional microbiologic methods, isolates that lacked a definitive identification by biochemical testing yielded genus- or species-level identifications in approximately 90% of cases by pyrosequencing. Improvements incorporated into the assay process during the period of clinical testing included software enhancements, improvements in sequencing reagents, and refinements in database search strategies. Coupled with isolation by bacteriologic culture and biochemical testing, DNA pyrosequencing-based bacterial identification was a valuable tool that markedly improved bacterial pathogen identification in a pediatric hospital setting.


Nature Biotechnology | 2015

Good laboratory practice for clinical next-generation sequencing informatics pipelines

Amy S. Gargis; Lisa Kalman; David P. Bick; Cristina da Silva; David Dimmock; Birgit Funke; Sivakumar Gowrisankar; Madhuri Hegde; Shashikant Kulkarni; Christopher E. Mason; Rakesh Nagarajan; Karl V. Voelkerding; Elizabeth A. Worthey; Nazneen Aziz; John Barnes; Sarah F. Bennett; Himani Bisht; Deanna M. Church; Zoya Dimitrova; Shaw R. Gargis; Nabil Hafez; Tina Hambuch; Fiona Hyland; Ruth Ann Luna; Duncan MacCannell; Tobias Mann; Megan R. McCluskey; Timothy K. McDaniel; Lilia Ganova-Raeva; Heidi L. Rehm

Amy S Gargis, Centers for Disease Control & Prevention Lisa Kalman, Centers for Disease Control & Prevention David P Bick, Medical College of Wisconsin Cristina da Silva, Emory University David P Dimmock, Medical College of Wisconsin Birgit H Funke, Partners Healthcare Personalized Medicine Sivakumar Gowrisankar, Partners Healthcare Personalized Medicine Madhuri Hegde, Emory University Shashikant Kulkarni, Washington University Christopher E Mason, Cornell University


Gut microbes | 2014

Gut microbiota influences low fermentable substrate diet efficacy in children with irritable bowel syndrome

Bruno P. Chumpitazi; Emily B. Hollister; Numan Oezguen; Cynthia M. Tsai; Ann R. McMeans; Ruth Ann Luna; Tor C. Savidge; James Versalovic; Robert J. Shulman

We sought to determine whether a low fermentable substrate diet (LFSD) decreases abdominal pain frequency in children with irritable bowel syndrome (IBS) and to identify potential microbial factors related to diet efficacy. Pain symptoms, stooling characteristics, breath hydrogen and methane, whole intestinal transit time, stool microbiome, and metabolite composition were collected and/or documented in eight children with IBS at baseline and during one week of an LFSD intervention. Pain frequency (P < 0.05), pain severity (P < 0.05), and pain-related interference with activities (P < 0.05) decreased in the subjects while on the LFSD. Responders vs. non-responders: four children (50%) were identified as responders (>50% decrease in abdominal pain frequency while on the LFSD). There were no differences between responders and non-responders with respect to hydrogen production, methane production, stooling characteristics, or gut transit time. Responders were characterized by increased pre-LFSD abundance of bacterial taxa belonging to the genera Sporobacter (P < 0.05) and Subdoligranulum (P < 0.02) and decreased abundance of taxa belonging to Bacteroides (P < 0.05) relative to non-responders. In parallel, stool metabolites differed between responders and non-responders and were associated with differences in microbiome composition. These pilot study results suggest that an LFSD may be effective in decreasing GI symptoms in children with IBS. Microbial factors such as gut microbiome composition and stool metabolites while on the diet may relate to LFSD efficacy.


Journal of Clinical Microbiology | 2011

Rapid Stool-Based Diagnosis of Clostridium difficile Infection by Real-Time PCR in a Children's Hospital

Ruth Ann Luna; Bobby L. Boyanton; Seema Mehta; Ebony M. Courtney; C. Renee Webb; Paula A. Revell; James Versalovic

ABSTRACT Clostridium difficile is a major cause of nosocomial antibiotic-associated infectious diarrhea and pseudomembranous colitis. Detection of C. difficile by anaerobic bacterial culture and/or cytotoxicity assays has been largely replaced by rapid enzyme immunoassays (EIA). However, due to the lack of sensitivity of stool EIA, we developed a multiplex real-time PCR assay targeting the C. difficile toxin genes tcdA and tcdB. Stool samples from hospitalized pediatric patients suspected of having C. difficile-associated disease were prospectively cultured on cycloserine-cefoxitin-fructose agar following alcohol shock. Six testing modalities were evaluated, including stool EIA, culture EIA, and real-time PCR (tcdA and tcdB) of cultured isolates and stool samples. Real-time PCR detection was performed with tcdA and tcdB gene-specific primers and hydrolysis probes using the LightCycler platforms (Roche Diagnostics, Indianapolis, IN). A total of 157 samples from 96 pediatric patients were analyzed. The sensitivities of stool real-time PCR and stool EIA were 95% and 35%, respectively, with a specificity of 100% for both methods. The lower limit of detection of the stool real-time PCR was 30 CFU/ml of stool sample per reaction for tcdA and tcdB. This study highlights the poor performance of stool toxin EIAs in pediatric settings. Direct detection of C. difficile toxin genes in stool samples by real-time PCR showed sensitivity superior to that of stool and culture EIAs and performance comparable to that of real-time PCR assay of cultured isolates. Real-time PCR of DNA from stool samples is a rapid and cost-effective diagnostic modality for children that should facilitate appropriate patient management and halt the practice of serial testing by EIA.


Nature Biotechnology | 2017

Towards standards for human fecal sample processing in metagenomic studies

Paul Igor Costea; Georg Zeller; Shinichi Sunagawa; Eric Pelletier; Adriana Alberti; Florence Levenez; Melanie Tramontano; Marja Driessen; Rajna Hercog; Ferris Elias Jung; Jens Roat Kultima; Matthew R. Hayward; Luis Pedro Coelho; Emma Allen-Vercoe; Laurie Bertrand; Michael Blaut; Jillian R.M. Brown; Thomas Carton; Stéphanie Cools-Portier; Michelle Daigneault; Muriel Derrien; Anne Druesne; Willem M. de Vos; B. Brett Finlay; Harry J. Flint; Francisco Guarner; Masahira Hattori; Hans G.H.J. Heilig; Ruth Ann Luna; Johan Van Hylckama Vlieg

Technical variation in metagenomic analysis must be minimized to confidently assess the contributions of microbiota to human health. Here we tested 21 representative DNA extraction protocols on the same fecal samples and quantified differences in observed microbial community composition. We compared them with differences due to library preparation and sample storage, which we contrasted with observed biological variation within the same specimen or within an individual over time. We found that DNA extraction had the largest effect on the outcome of metagenomic analysis. To rank DNA extraction protocols, we considered resulting DNA quantity and quality, and we ascertained biases in estimates of community diversity and the ratio between Gram-positive and Gram-negative bacteria. We recommend a standardized DNA extraction method for human fecal samples, for which transferability across labs was established and which was further benchmarked using a mock community of known composition. Its adoption will improve comparability of human gut microbiome studies and facilitate meta-analyses.


Expert Review of Anti-infective Therapy | 2010

Molecular microbiological methods in the diagnosis of neonatal sepsis

Mohan Pammi Venkatesh; Angela Flores; Ruth Ann Luna; James Versalovic

Neonatal sepsis is a major cause of neonatal mortality and morbidity. The current gold standard for diagnosis of sepsis, namely blood culture, suffers from low sensitivity and a reporting delay of approximately 48–72 h. Rapid detection of sepsis and institution of antimicrobial therapy may improve patient outcomes. Rapid and sensitive tests that can inform clinicians regarding the institution or optimization of antimicrobial therapy are urgently needed. The ideal diagnostic test should have adequate specificity and negative predictive value to reliably exclude sepsis and avoid unnecessary antibiotic therapy. We comprehensively searched for neonatal studies that evaluated molecular methods for diagnosis of sepsis. We identified 19 studies that were assessed with respect to assay methodology and diagnostic characteristics. In addition, we also reviewed newer molecular microbiological assays of relevance that have not been fully evaluated in neonates. Molecular methods offer distinct advantages over blood cultures, including increased sensitivity and rapid diagnosis. However, diagnostic accuracy and cost–effectiveness should be established before implementation in clinical practice.


The American Journal of Gastroenterology | 2015

Serial Fecal Microbiota Transplantation Alters Mucosal Gene Expression in Pediatric Ulcerative Colitis

Richard Kellermayer; Dorottya Nagy-Szakal; R. Alan Harris; Ruth Ann Luna; Milena Pitashny; Deborah Schady; Sabina Mir; Monica E. Lopez; Mark A. Gilger; John W. Belmont; Emily B. Hollister; James Versalovic

Serial Fecal Microbiota Transplantation Alters Mucosal Gene Expression in Pediatric Ulcerative Colitis


Cellular and molecular gastroenterology and hepatology | 2017

Distinct Microbiome-Neuroimmune Signatures Correlate With Functional Abdominal Pain in Children With Autism Spectrum Disorder

Ruth Ann Luna; Numan Oezguen; Miriam A. Balderas; Alamelu Venkatachalam; Jessica K. Runge; James Versalovic; Jeremy Veenstra-VanderWeele; George M. Anderson; Tor C. Savidge; Kent C. Williams

Background & Aims Emerging data on the gut microbiome in autism spectrum disorder (ASD) suggest that altered host–microbe interactions may contribute to disease symptoms. Although gut microbial communities in children with ASD are reported to differ from individuals with neurotypical development, it is not known whether these bacteria induce pathogenic neuroimmune signals. Methods Because commensal clostridia interactions with the intestinal mucosa can regulate disease-associated cytokine and serotonergic pathways in animal models, we evaluated whether microbiome-neuroimmune profiles (from rectal biopsy specimens and blood) differed in ASD children with functional gastrointestinal disorders (ASD-FGID, n = 14) compared with neurotypical (NT) children with FGID (NT-FGID, n = 15) and without abdominal pain (NT, n = 6). Microbial 16S ribosomal DNA community signatures, cytokines, and serotonergic metabolites were quantified and correlated with gastrointestinal symptoms. Results A significant increase in several mucosa-associated Clostridiales was observed in ASD-FGID, whereas marked decreases in Dorea and Blautia, as well as Sutterella, were evident. Stratification by abdominal pain showed multiple organisms in ASD-FGID that correlated significantly with cytokines (interleukin [IL]6, IL1, IL17A, and interferon-γ). Group comparisons showed that IL6 and tryptophan release by mucosal biopsy specimens was highest in ASD children with abdominal pain, whereas serotonergic metabolites generally were increased in children with FGIDs. Furthermore, proinflammatory cytokines correlated significantly with several Clostridiales previously reported to associate with ASD, as did tryptophan and serotonin. Conclusions Our findings identify distinctive mucosal microbial signatures in ASD children with FGID that correlate with cytokine and tryptophan homeostasis. Future studies are needed to establish whether these disease-associated Clostridiales species confer early pathogenic signals in children with ASD and FGID.

Collaboration


Dive into the Ruth Ann Luna's collaboration.

Top Co-Authors

Avatar

James Versalovic

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert J. Shulman

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Tor C. Savidge

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Numan Oezguen

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jessica K. Runge

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge